Addis & Hill Inc Reduces Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Addis & Hill Inc lessened its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 45.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 163,386 shares of the company’s stock after selling 136,614 shares during the quarter. Neumora Therapeutics comprises approximately 1.3% of Addis & Hill Inc’s portfolio, making the stock its 11th largest position. Addis & Hill Inc owned about 0.10% of Neumora Therapeutics worth $1,732,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Ballentine Partners LLC acquired a new position in Neumora Therapeutics in the third quarter valued at about $178,000. Auour Investments LLC purchased a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at approximately $3,302,000. Intech Investment Management LLC purchased a new stake in shares of Neumora Therapeutics in the 3rd quarter valued at approximately $175,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Neumora Therapeutics by 139.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company’s stock worth $9,224,000 after acquiring an additional 406,891 shares during the last quarter. Finally, Cerity Partners LLC purchased a new position in shares of Neumora Therapeutics during the 3rd quarter worth approximately $3,209,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Trading Up 3.0 %

Shares of NASDAQ NMRA opened at $1.74 on Monday. The company’s 50-day moving average price is $5.17 and its 200 day moving average price is $9.68. Neumora Therapeutics, Inc. has a 52 week low of $1.60 and a 52 week high of $21.00. The stock has a market cap of $281.12 million, a price-to-earnings ratio of -0.93 and a beta of 2.50.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. cut Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $18.00 to $15.00 in a research note on Tuesday, November 5th. Bank of America decreased their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Neumora Therapeutics in a report on Friday. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a report on Thursday, January 2nd. Finally, William Blair reissued an “outperform” rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Neumora Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.